Key Takeaways
-
62.8% of women showed photographic improvement — nearly four times the improvement rate seen in the placebo group (17.5%), after 12 mesotherapy sessions over 16 weeks.
-
Hair diameter significantly increased — treated hairs became measurably thicker, confirmed by both morphometric measurement and ultrastructural examination under electron microscopy.
-
Earlier intervention produces better results — the study found a significant negative correlation between disease duration and improvement, meaning women who started treatment sooner responded better.
-
Minimal side effects — no significant difference in adverse events between treatment and placebo groups, supporting the safety profile of mesotherapy delivery.
-
This was one of the largest controlled mesotherapy trials for female hair loss — 126 women participated, making it a substantial evidence base for this treatment approach.
Evidence at a Glance
| Evidence Level |
Level 2b — Controlled clinical trial with 126 patients |
| Sample Size |
126 women (86 treatment, 40 placebo control) |
| Key Result |
62.8% photographic improvement vs 17.5% in controls (P < 0.05) |
| Treatment Duration |
12 sessions over 16 weeks, evaluated at week 18 |
| Outcome Measures |
Photographic assessment, hair pull test, hair diameter, patient self-assessment, ultrastructural examination |
| Safety |
Minimal side effects, no significant difference between groups |
About This Study
| Authors |
N. Moftah, G. Abd-Elaziz, N. Ahmed, Y. Hamed, B. Ghannam, M. Ibrahim |
| Journal |
Journal of the European Academy of Dermatology and Venereology (JEADV) |
| Year |
2013 |
| Volume/Pages |
Vol. 27, Issue 6, pp. 686–693 |
| Type |
Controlled clinical trial |
| PMID |
22486925 |
| DOI |
10.1111/j.1468-3083.2012.04535.x |
| Full Paper |
View on PubMed → |
Note: This is a plain-language summary of the published research paper. The original study was conducted independently and is not affiliated with Hairgenetix. We present this summary to make scientific research more accessible to people experiencing hair loss.
Reviewed by: Esther Bodde, MSc — Health Scientist and Medical Research Analyst at Hairgenetix. Esther holds a Master of Science degree and specialises in translating clinical research into clear, evidence-based consumer information. This summary was reviewed for scientific accuracy, fair representation of results, and clear communication of study limitations.
Why This Research Matters
Female pattern hair loss (FPHL) affects an estimated 40% of women by the age of 50, yet treatment options have historically been far more limited than those available to men. While men can use finasteride, dutasteride, and minoxidil, women's options have largely been restricted to topical minoxidil — which many find messy, inconvenient, and only modestly effective.
This 2013 study by Moftah and colleagues addressed a critical gap: could dutasteride — a powerful 5-alpha reductase inhibitor normally taken orally for male hair loss — be safely and effectively delivered directly to the scalp via mesotherapy injections in women? Oral dutasteride is generally contraindicated in women of childbearing potential due to teratogenic risks, but delivering it locally through scalp micro-injections could theoretically minimise systemic exposure while maximising local effect.
With 126 participants, this was one of the largest controlled trials to evaluate mesotherapy for female hair loss. The results — a 62.8% photographic improvement rate compared to just 17.5% in controls — provided some of the strongest evidence that mesotherapy could be a viable treatment pathway for women experiencing pattern hair loss.
What The Researchers Did
The researchers recruited 126 women diagnosed with female pattern hair loss and divided them into two groups:
-
Treatment group (86 women): Received scalp injections of a preparation containing 0.05% dutasteride dissolved in a solution of dexpanthenol, biotin, and pyridoxine (vitamin B6). Each session involved 2 mL of this solution delivered via mesotherapy technique — multiple micro-injections across the affected scalp area.
-
Control group (40 women): Received identical-looking injections of saline (salt water) as a placebo, using the same mesotherapy technique.
The treatment schedule was carefully structured: weekly sessions for the first 8 weeks, then two sessions spaced two weeks apart, followed by one final session after a four-week gap. This gave a total of 12 sessions spread over approximately 16 weeks.
Results were assessed at week 18 using multiple objective and subjective measures: standardised photography evaluated by blinded assessors, a hair pull test (counting hairs that come out when gently tugging), precise measurement of hair shaft diameter, and patient self-assessment questionnaires. Additionally, three patients underwent ultrastructural examination of their hair under electron microscopy — providing microscopic-level evidence of hair quality changes.
Understanding the Research Methods
Why use a placebo control? The saline-injection control group was essential for determining whether the improvement was due to the dutasteride itself or simply from the mesotherapy procedure (the injection process stimulates some local blood flow and growth factor release on its own). By comparing against saline injections rather than no treatment, the researchers isolated the specific contribution of the dutasteride preparation.
Why multiple assessment methods? Using five different outcome measures — photographic, hair pull test, diameter measurement, self-assessment, and ultrastructural examination — provides a much more robust picture than any single metric alone. Photography shows overall visual improvement, diameter measurement captures hair thickening, and electron microscopy reveals structural repair at the cellular level. This multi-modal approach makes the findings more credible.
What is the photographic assessment method? Standardised clinical photography taken under identical lighting and positioning conditions allows blinded assessors (who don't know which treatment the patient received) to evaluate whether hair density has visibly improved. This removes the bias that can occur when patients or treating doctors assess their own results.
What about the unequal group sizes? The treatment group (86 patients) was larger than the control group (40 patients), which is a common design in clinical trials where the primary interest is characterising the treatment effect. However, this 2:1 ratio still provides adequate statistical power for detecting meaningful differences.
What They Found
62.8% showed photographic improvement: Nearly two-thirds of women receiving the dutasteride mesotherapy demonstrated visible hair improvement on standardised photographs, compared with only 17.5% in the saline control group. This 3.6-fold difference was statistically significant (P < 0.05).
Hair diameter significantly increased: Morphometric measurement of individual hair shafts showed that treated hairs became measurably thicker after the 12-session treatment protocol. This increase in hair diameter was statistically significant (P < 0.05), indicating that the treatment wasn't just growing new hairs — it was also strengthening existing ones.
Hair pull test improved: The mean number of hairs extracted during a standardised pull test significantly decreased in the treatment group (P < 0.05), indicating reduced hair shedding and stronger anchorage of hairs within the follicle.
Patients noticed the difference: Self-assessment questionnaires confirmed that treated patients perceived significant improvement in their hair compared with controls (P < 0.05). This alignment between objective measurements and patient perception strengthens the clinical meaningfulness of the results.
Ultrastructural repair confirmed: Electron microscopy of hair samples from three patients revealed that damaged or absent cuticle layers — the protective outer surface of the hair shaft — were restored after treatment. Before therapy, one patient showed completely absent cuticle and another showed focal cuticle destruction. Both showed cuticle recovery post-treatment.
Earlier treatment works better: A statistically significant negative correlation was found between disease duration and degree of improvement (P < 0.05). Women who had been experiencing hair loss for a shorter time responded better to treatment — reinforcing the clinical principle that early intervention yields the best outcomes.
Figure 1: Summary of key findings from Moftah et al. (2013). Left: photographic improvement rates in treatment vs control groups. Centre: treatment protocol timeline showing session frequency. Right: overview of outcome measures and their statistical significance. Data source: JEADV 2013;27:686-93.
How This Treatment Works: The Biological Mechanisms
Dutasteride's role: Dutasteride is a dual 5-alpha reductase inhibitor — it blocks both Type I and Type II enzymes that convert testosterone into dihydrotestosterone (DHT). DHT is the primary hormone responsible for miniaturising hair follicles in androgenetic alopecia. By inhibiting DHT production locally at the follicle level, dutasteride helps prevent further follicle shrinkage and may allow partially miniaturised follicles to recover.
Why mesotherapy delivery matters: Oral dutasteride carries systemic risks — particularly for women, as it can cause birth defects. Mesotherapy delivers the drug directly to the target tissue through multiple shallow intradermal injections (typically 4mm depth). This local delivery achieves high drug concentrations at the hair follicle while minimising systemic absorption, potentially offering the therapeutic benefits without the systemic risks.
The supporting ingredients: The formulation included dexpanthenol (provitamin B5, which supports hair shaft hydration and flexibility), biotin (vitamin B7, essential for keratin production), and pyridoxine (vitamin B6, involved in amino acid metabolism for hair protein synthesis). While these vitamins alone have limited evidence for reversing hair loss, they may support the structural recovery of treated follicles.
The mesotherapy procedure itself: Beyond delivering active ingredients, the micro-injection process causes controlled micro-trauma to the scalp, which triggers a wound-healing cascade that releases growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This mechanism is similar to the growth factor release seen with microneedling, potentially providing an additive benefit on top of the pharmacological effect.
Clinical Interpretation
The 62.8% response rate is clinically meaningful, particularly for female hair loss where treatment options are limited. However, several factors should be considered when interpreting these results:
Photographic improvement ≠ complete regrowth: The photographic assessment measured whether there was visible improvement, not the degree of improvement. Some women in the 62.8% may have shown modest improvement while others showed dramatic results. The study doesn't break down the degree of response.
The placebo response was 17.5%: This is notable because the control group received saline mesotherapy injections. This suggests that even the injection procedure alone — without active drug — produced some improvement in about 1 in 6 women, likely through the micro-trauma and growth factor release mechanism. The true drug effect is the difference: approximately 45 percentage points of additional benefit from the dutasteride preparation.
Short-term evaluation: Assessment at week 18 (just 2 weeks after the final session) captures the immediate treatment response but doesn't tell us how long the benefits last. Hair loss is a chronic condition, and the durability of mesotherapy results — and whether maintenance sessions are needed — remains an important unanswered question.
How This Compares With Other Research
| Study |
Treatment |
Subjects |
Key Finding |
| Moftah 2013 (this study) |
Dutasteride mesotherapy |
126 women |
62.8% photographic improvement vs 17.5% control |
| Dhurat 2013 |
Microneedling + minoxidil |
100 men |
+91.4 hairs/cm² vs +22.2 with minoxidil alone |
| Gupta 2022 (meta-analysis) |
Microneedling ± minoxidil |
Multiple trials pooled |
Microneedling significantly outperformed minoxidil alone |
| Sun 2022 (systematic review) |
Mesotherapy (various agents) |
Review of multiple trials |
Mesotherapy showed promise but evidence quality varied |
This study is particularly notable because it focused exclusively on women — a population underrepresented in hair loss research. While direct comparison across studies is limited by different methodologies and populations, the 62.8% improvement rate compares favourably with response rates reported for minoxidil 2% in women (typically 30-40% showing visible improvement).
Treatment Protocol Details
| Active Ingredient |
0.05% dutasteride in dexpanthenol, biotin, and pyridoxine solution |
| Injection Volume |
2 mL per session |
| Delivery Method |
Mesotherapy — multiple intradermal micro-injections across the affected scalp area |
| Session Schedule |
Weekly × 8 weeks → biweekly × 2 sessions → 1 session after 4-week gap |
| Total Sessions |
12 sessions over approximately 16 weeks |
| Assessment Point |
Week 18 (2 weeks after final session) |
| Control Treatment |
Identical mesotherapy procedure using normal saline |
| Patient Population |
Women diagnosed with female pattern hair loss (FPHL) |
Important note: Mesotherapy with dutasteride is a clinical procedure that must be performed by a qualified dermatologist or trichologist. Dutasteride is a prescription medication and should never be self-administered. The protocol described here is from a controlled clinical trial and may differ from protocols used in clinical practice.
Research Limitations to Consider
-
Not fully randomised: While the study used a control group, the exact randomisation methodology is not detailed in the abstract. True randomised controlled trials (RCTs) are the gold standard for eliminating selection bias.
-
Short follow-up: Assessment at week 18 (only 2 weeks after the final treatment session) doesn't establish the durability of results. Hair loss is a chronic condition, and understanding whether benefits persist — and whether maintenance treatments are needed — is critical for practical clinical use.
-
Unequal group sizes: The 2:1 ratio (86 treatment vs 40 control) may affect statistical power for detecting certain differences, though the sample sizes are still adequate for the primary analysis.
-
Limited ultrastructural data: Only 3 patients underwent electron microscopy examination. While the ultrastructural findings are interesting, they cannot be generalised to the broader study population.
-
Photographic assessment binary: The study reports the percentage of patients showing improvement but doesn't detail the degree or magnitude of improvement within responders.
-
No long-term safety data: While minimal side effects were noted during the 16-week treatment period, long-term safety of repeated intradermal dutasteride delivery — particularly regarding local and systemic effects — was not assessed.
-
Single-centre study: The trial was conducted at a single centre, which may limit generalisability to different populations and practice settings.
What This Means For Your Hair
This study provides meaningful evidence that mesotherapy — the direct delivery of active ingredients into the scalp through micro-injections — can be an effective treatment approach for female pattern hair loss. Key practical implications:
-
Mesotherapy can bypass the limitations of topical application: Rather than relying on absorption through the skin barrier (as with topical minoxidil), mesotherapy delivers active ingredients directly to the depth where hair follicles reside. This is particularly relevant for ingredients that don't penetrate the scalp well on their own.
-
The micro-injection process itself may contribute to the results: The 17.5% improvement in the saline control group suggests that even the mesotherapy procedure alone has some therapeutic effect — likely through growth factor stimulation from the controlled micro-trauma. This principle is shared with microneedling, which Hairgenetix products are specifically designed to complement.
-
Early intervention matters: The finding that shorter disease duration correlated with better outcomes reinforces a consistent message across hair loss research — the sooner you start treating hair loss, the better your results will be. Hair follicles that are still miniaturising are more responsive than those that have been dormant for years.
-
At-home microneedling follows the same delivery principle: While mesotherapy requires a clinical setting, at-home microneedling with a derma roller creates similar micro-channels in the scalp that enhance the penetration and effectiveness of topical treatments. The copper peptide serums in the Hairgenetix protocol are formulated to take advantage of exactly this enhanced delivery mechanism.
Key Terms Explained
- Mesotherapy
- A medical procedure involving multiple small injections of pharmaceutical or cosmetic substances directly into the middle layer of skin (mesoderm). In hair loss treatment, these injections target the scalp at the depth where hair follicles reside, delivering active ingredients directly to the treatment site rather than relying on absorption through the skin surface.
- Dutasteride
- A prescription medication that inhibits both Type I and Type II 5-alpha reductase enzymes — the enzymes that convert testosterone into DHT (dihydrotestosterone). It is more potent than finasteride, which only blocks Type II. Dutasteride is approved for benign prostatic hyperplasia and is used off-label for hair loss.
- Female Pattern Hair Loss (FPHL)
- Also called female androgenetic alopecia, this is the most common form of hair loss in women. It typically presents as diffuse thinning across the top of the scalp, often with a widening central part. Unlike male pattern hair loss, the frontal hairline is usually preserved in women.
- 5-Alpha Reductase
- An enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). DHT binds to receptors in genetically sensitive hair follicles, causing them to shrink (miniaturise) over time. Blocking this enzyme reduces local DHT levels and can slow or reverse follicle miniaturisation.
- Morphometric Measurement
- The precise measurement of physical characteristics — in this case, the diameter (thickness) of individual hair shafts. Thicker hair shafts indicate healthier, more robust follicle function, while thinner shafts suggest miniaturisation is occurring.
- Ultrastructural Examination
- Examination of biological tissue at extremely high magnification using an electron microscope. This can reveal details invisible under a regular microscope, such as the condition of the hair cuticle (the protective outer layer of overlapping cells on the hair shaft).
- Hair Pull Test
- A simple diagnostic test where a clinician grasps approximately 60 hairs between thumb and forefinger and pulls firmly but gently. Normally, fewer than 6 hairs should come out. A higher number suggests active hair shedding and can be used to monitor treatment response.
- Controlled Clinical Trial
- A study design where one group receives the treatment being tested while another group (the control) receives a placebo or standard treatment. This allows researchers to determine whether observed effects are due to the treatment itself rather than natural variation, the passage of time, or the placebo effect.
Further Reading
For more peer-reviewed studies on hair loss and copper peptide therapy, see our full research hub.
Frequently Asked Questions
Is dutasteride mesotherapy safe for women?
In this study, the treatment showed minimal side effects with no statistically significant difference in adverse events between the treatment and control groups. The key advantage of mesotherapy delivery over oral dutasteride is that it minimises systemic absorption, which is important because oral dutasteride is generally contraindicated in women of childbearing potential due to teratogenic risks. However, this study only covered a 16-week treatment period, and long-term safety data for repeated intradermal dutasteride delivery is limited. Any woman considering this treatment should discuss it thoroughly with a qualified dermatologist, and women who are pregnant or planning pregnancy should avoid dutasteride in any form.
How does mesotherapy compare with minoxidil for women?
The 62.8% photographic improvement rate in this study compares favourably with published response rates for topical minoxidil 2% in women, which typically range from 30-40% showing visible improvement. However, direct comparison is difficult because the studies used different assessment methods, populations, and timeframes. Minoxidil has the advantage of decades of long-term safety data and at-home convenience, while mesotherapy requires clinical visits but may offer better outcomes. Many clinicians now use mesotherapy as a complement to home topical treatments rather than as a replacement.
Can I get dutasteride mesotherapy at my local dermatologist?
Mesotherapy for hair loss is available at many dermatology clinics and trichology centres, but the specific formulation used varies between practitioners. Some use dutasteride, others use minoxidil, platelet-rich plasma (PRP), or various cocktail combinations. Not all clinics offer the exact protocol used in this study. When seeking treatment, ask specifically about the active ingredients, concentrations, and number of sessions in their protocol, and whether they can reference published clinical evidence supporting their approach.
Why did the saline control group also show improvement?
The 17.5% improvement rate in the saline group is actually expected and informative. The mesotherapy injection process itself causes controlled micro-trauma to the scalp, which triggers a wound-healing response that releases growth factors such as PDGF, VEGF, and TGF-β. This is the same principle behind microneedling's effectiveness. Additionally, some improvement may be attributed to the placebo effect and the natural fluctuation of hair loss over time. This is precisely why having a control group is essential — it allows researchers to separate the specific drug effect (approximately 45 percentage points) from these non-specific effects.
How long do mesotherapy results last?
This study assessed results at week 18 (just 2 weeks after the final session), so it doesn't provide data on long-term durability. Clinical experience suggests that maintenance sessions are typically needed to sustain results, as the underlying genetic predisposition to hair loss doesn't change. The optimal maintenance schedule — whether monthly, quarterly, or otherwise — is not well established in the literature and likely varies between individuals. This is an area where more research is needed.
Does the finding about disease duration mean it's too late for me?
Not necessarily. The study found that women with shorter disease duration responded better, but this doesn't mean women with longer-standing hair loss can't benefit at all — it means the magnitude of improvement tends to be greater in earlier stages. Hair follicles go through a gradual miniaturisation process over years before they become permanently inactive. As long as follicles are still present (even if producing only fine vellus hairs), there is potential for response to treatment. A trichologist can assess your follicle status using dermoscopy to help set realistic expectations.
Is at-home microneedling similar to mesotherapy?
Both procedures create micro-channels in the scalp, but they differ in important ways. Mesotherapy involves injecting liquid preparations containing active ingredients directly into the skin using a fine needle or injection gun, typically reaching the dermis (deeper layer). Microneedling creates tiny puncture channels that allow topically applied products to penetrate more effectively — the products are applied to the surface and absorbed through the channels rather than being injected. While microneedling doesn't achieve the same depth of drug delivery as mesotherapy, it triggers similar wound-healing responses and growth factor release. At-home microneedling with products like copper peptide serums provides a practical, accessible alternative that shares some of the same biological mechanisms.
What role do the supporting ingredients (biotin, dexpanthenol, pyridoxine) play?
The formulation used in this study wasn't dutasteride alone — it included dexpanthenol (provitamin B5), biotin (vitamin B7), and pyridoxine (vitamin B6). These vitamins play supporting roles: dexpanthenol hydrates and strengthens the hair shaft, biotin is involved in keratin production, and pyridoxine supports amino acid metabolism needed for hair protein synthesis. However, the study design doesn't allow us to separate the individual contributions of each ingredient. The primary active ingredient for anti-androgenic effect was dutasteride; the vitamins likely provided nutritional support to the follicle environment rather than direct anti-hair-loss activity.
Original Study Citation
Moftah, N., Abd-Elaziz, G., Ahmed, N., Hamed, Y., Ghannam, B., & Ibrahim, M. (2013). Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. Journal of the European Academy of Dermatology and Venereology, 27(6), 686–693. https://doi.org/10.1111/j.1468-3083.2012.04535.x
How to Cite This Summary
APA: Hairgenetix. (2025). Mesotherapy for female hair loss: 62.8% showed improvement — Plain-language study summary. Hairgenetix Research Library. https://hairgenetix.com/blogs/articles/mesotherapy-female-hair-loss-dutasteride-moftah-2013
Informal: According to a 2013 clinical trial of 126 women published in JEADV, dutasteride mesotherapy produced photographic improvement in 62.8% of patients compared to 17.5% with placebo (Moftah et al., 2013). Summarised by Hairgenetix at hairgenetix.com.
Last reviewed and updated: March 2025 · Based on original publication: June 2013
Why Hairgenetix Focuses on Science-Backed Treatments
This study demonstrates that delivering active ingredients directly to the scalp — rather than relying on surface application alone — produces significantly better results. This delivery principle is at the core of the Hairgenetix approach.
Our copper peptide serum is formulated to work with at-home microneedling, creating micro-channels that enhance ingredient penetration — the same concept that makes clinical mesotherapy so effective, adapted for safe home use. Combined with our derma roller system, you can apply the science of enhanced scalp delivery without clinical visits.
Browse the Hairgenetix Collection →
Mesotherapy for Female Hair Loss: 62.8% Showed Improvement (2013 Study, 126 Women)
Key Takeaways
Evidence at a Glance
About This Study
Why This Research Matters
Female pattern hair loss (FPHL) affects an estimated 40% of women by the age of 50, yet treatment options have historically been far more limited than those available to men. While men can use finasteride, dutasteride, and minoxidil, women's options have largely been restricted to topical minoxidil — which many find messy, inconvenient, and only modestly effective.
This 2013 study by Moftah and colleagues addressed a critical gap: could dutasteride — a powerful 5-alpha reductase inhibitor normally taken orally for male hair loss — be safely and effectively delivered directly to the scalp via mesotherapy injections in women? Oral dutasteride is generally contraindicated in women of childbearing potential due to teratogenic risks, but delivering it locally through scalp micro-injections could theoretically minimise systemic exposure while maximising local effect.
With 126 participants, this was one of the largest controlled trials to evaluate mesotherapy for female hair loss. The results — a 62.8% photographic improvement rate compared to just 17.5% in controls — provided some of the strongest evidence that mesotherapy could be a viable treatment pathway for women experiencing pattern hair loss.
What The Researchers Did
The researchers recruited 126 women diagnosed with female pattern hair loss and divided them into two groups:
The treatment schedule was carefully structured: weekly sessions for the first 8 weeks, then two sessions spaced two weeks apart, followed by one final session after a four-week gap. This gave a total of 12 sessions spread over approximately 16 weeks.
Results were assessed at week 18 using multiple objective and subjective measures: standardised photography evaluated by blinded assessors, a hair pull test (counting hairs that come out when gently tugging), precise measurement of hair shaft diameter, and patient self-assessment questionnaires. Additionally, three patients underwent ultrastructural examination of their hair under electron microscopy — providing microscopic-level evidence of hair quality changes.
Understanding the Research Methods
Why use a placebo control? The saline-injection control group was essential for determining whether the improvement was due to the dutasteride itself or simply from the mesotherapy procedure (the injection process stimulates some local blood flow and growth factor release on its own). By comparing against saline injections rather than no treatment, the researchers isolated the specific contribution of the dutasteride preparation.
Why multiple assessment methods? Using five different outcome measures — photographic, hair pull test, diameter measurement, self-assessment, and ultrastructural examination — provides a much more robust picture than any single metric alone. Photography shows overall visual improvement, diameter measurement captures hair thickening, and electron microscopy reveals structural repair at the cellular level. This multi-modal approach makes the findings more credible.
What is the photographic assessment method? Standardised clinical photography taken under identical lighting and positioning conditions allows blinded assessors (who don't know which treatment the patient received) to evaluate whether hair density has visibly improved. This removes the bias that can occur when patients or treating doctors assess their own results.
What about the unequal group sizes? The treatment group (86 patients) was larger than the control group (40 patients), which is a common design in clinical trials where the primary interest is characterising the treatment effect. However, this 2:1 ratio still provides adequate statistical power for detecting meaningful differences.
What They Found
Figure 1: Summary of key findings from Moftah et al. (2013). Left: photographic improvement rates in treatment vs control groups. Centre: treatment protocol timeline showing session frequency. Right: overview of outcome measures and their statistical significance. Data source: JEADV 2013;27:686-93.
How This Treatment Works: The Biological Mechanisms
Dutasteride's role: Dutasteride is a dual 5-alpha reductase inhibitor — it blocks both Type I and Type II enzymes that convert testosterone into dihydrotestosterone (DHT). DHT is the primary hormone responsible for miniaturising hair follicles in androgenetic alopecia. By inhibiting DHT production locally at the follicle level, dutasteride helps prevent further follicle shrinkage and may allow partially miniaturised follicles to recover.
Why mesotherapy delivery matters: Oral dutasteride carries systemic risks — particularly for women, as it can cause birth defects. Mesotherapy delivers the drug directly to the target tissue through multiple shallow intradermal injections (typically 4mm depth). This local delivery achieves high drug concentrations at the hair follicle while minimising systemic absorption, potentially offering the therapeutic benefits without the systemic risks.
The supporting ingredients: The formulation included dexpanthenol (provitamin B5, which supports hair shaft hydration and flexibility), biotin (vitamin B7, essential for keratin production), and pyridoxine (vitamin B6, involved in amino acid metabolism for hair protein synthesis). While these vitamins alone have limited evidence for reversing hair loss, they may support the structural recovery of treated follicles.
The mesotherapy procedure itself: Beyond delivering active ingredients, the micro-injection process causes controlled micro-trauma to the scalp, which triggers a wound-healing cascade that releases growth factors including platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). This mechanism is similar to the growth factor release seen with microneedling, potentially providing an additive benefit on top of the pharmacological effect.
Clinical Interpretation
The 62.8% response rate is clinically meaningful, particularly for female hair loss where treatment options are limited. However, several factors should be considered when interpreting these results:
Photographic improvement ≠ complete regrowth: The photographic assessment measured whether there was visible improvement, not the degree of improvement. Some women in the 62.8% may have shown modest improvement while others showed dramatic results. The study doesn't break down the degree of response.
The placebo response was 17.5%: This is notable because the control group received saline mesotherapy injections. This suggests that even the injection procedure alone — without active drug — produced some improvement in about 1 in 6 women, likely through the micro-trauma and growth factor release mechanism. The true drug effect is the difference: approximately 45 percentage points of additional benefit from the dutasteride preparation.
Short-term evaluation: Assessment at week 18 (just 2 weeks after the final session) captures the immediate treatment response but doesn't tell us how long the benefits last. Hair loss is a chronic condition, and the durability of mesotherapy results — and whether maintenance sessions are needed — remains an important unanswered question.
How This Compares With Other Research
This study is particularly notable because it focused exclusively on women — a population underrepresented in hair loss research. While direct comparison across studies is limited by different methodologies and populations, the 62.8% improvement rate compares favourably with response rates reported for minoxidil 2% in women (typically 30-40% showing visible improvement).
Treatment Protocol Details
Important note: Mesotherapy with dutasteride is a clinical procedure that must be performed by a qualified dermatologist or trichologist. Dutasteride is a prescription medication and should never be self-administered. The protocol described here is from a controlled clinical trial and may differ from protocols used in clinical practice.
Research Limitations to Consider
What This Means For Your Hair
This study provides meaningful evidence that mesotherapy — the direct delivery of active ingredients into the scalp through micro-injections — can be an effective treatment approach for female pattern hair loss. Key practical implications:
Key Terms Explained
Further Reading
For more peer-reviewed studies on hair loss and copper peptide therapy, see our full research hub.
Frequently Asked Questions
Is dutasteride mesotherapy safe for women?
In this study, the treatment showed minimal side effects with no statistically significant difference in adverse events between the treatment and control groups. The key advantage of mesotherapy delivery over oral dutasteride is that it minimises systemic absorption, which is important because oral dutasteride is generally contraindicated in women of childbearing potential due to teratogenic risks. However, this study only covered a 16-week treatment period, and long-term safety data for repeated intradermal dutasteride delivery is limited. Any woman considering this treatment should discuss it thoroughly with a qualified dermatologist, and women who are pregnant or planning pregnancy should avoid dutasteride in any form.
How does mesotherapy compare with minoxidil for women?
The 62.8% photographic improvement rate in this study compares favourably with published response rates for topical minoxidil 2% in women, which typically range from 30-40% showing visible improvement. However, direct comparison is difficult because the studies used different assessment methods, populations, and timeframes. Minoxidil has the advantage of decades of long-term safety data and at-home convenience, while mesotherapy requires clinical visits but may offer better outcomes. Many clinicians now use mesotherapy as a complement to home topical treatments rather than as a replacement.
Can I get dutasteride mesotherapy at my local dermatologist?
Mesotherapy for hair loss is available at many dermatology clinics and trichology centres, but the specific formulation used varies between practitioners. Some use dutasteride, others use minoxidil, platelet-rich plasma (PRP), or various cocktail combinations. Not all clinics offer the exact protocol used in this study. When seeking treatment, ask specifically about the active ingredients, concentrations, and number of sessions in their protocol, and whether they can reference published clinical evidence supporting their approach.
Why did the saline control group also show improvement?
The 17.5% improvement rate in the saline group is actually expected and informative. The mesotherapy injection process itself causes controlled micro-trauma to the scalp, which triggers a wound-healing response that releases growth factors such as PDGF, VEGF, and TGF-β. This is the same principle behind microneedling's effectiveness. Additionally, some improvement may be attributed to the placebo effect and the natural fluctuation of hair loss over time. This is precisely why having a control group is essential — it allows researchers to separate the specific drug effect (approximately 45 percentage points) from these non-specific effects.
How long do mesotherapy results last?
This study assessed results at week 18 (just 2 weeks after the final session), so it doesn't provide data on long-term durability. Clinical experience suggests that maintenance sessions are typically needed to sustain results, as the underlying genetic predisposition to hair loss doesn't change. The optimal maintenance schedule — whether monthly, quarterly, or otherwise — is not well established in the literature and likely varies between individuals. This is an area where more research is needed.
Does the finding about disease duration mean it's too late for me?
Not necessarily. The study found that women with shorter disease duration responded better, but this doesn't mean women with longer-standing hair loss can't benefit at all — it means the magnitude of improvement tends to be greater in earlier stages. Hair follicles go through a gradual miniaturisation process over years before they become permanently inactive. As long as follicles are still present (even if producing only fine vellus hairs), there is potential for response to treatment. A trichologist can assess your follicle status using dermoscopy to help set realistic expectations.
Is at-home microneedling similar to mesotherapy?
Both procedures create micro-channels in the scalp, but they differ in important ways. Mesotherapy involves injecting liquid preparations containing active ingredients directly into the skin using a fine needle or injection gun, typically reaching the dermis (deeper layer). Microneedling creates tiny puncture channels that allow topically applied products to penetrate more effectively — the products are applied to the surface and absorbed through the channels rather than being injected. While microneedling doesn't achieve the same depth of drug delivery as mesotherapy, it triggers similar wound-healing responses and growth factor release. At-home microneedling with products like copper peptide serums provides a practical, accessible alternative that shares some of the same biological mechanisms.
What role do the supporting ingredients (biotin, dexpanthenol, pyridoxine) play?
The formulation used in this study wasn't dutasteride alone — it included dexpanthenol (provitamin B5), biotin (vitamin B7), and pyridoxine (vitamin B6). These vitamins play supporting roles: dexpanthenol hydrates and strengthens the hair shaft, biotin is involved in keratin production, and pyridoxine supports amino acid metabolism needed for hair protein synthesis. However, the study design doesn't allow us to separate the individual contributions of each ingredient. The primary active ingredient for anti-androgenic effect was dutasteride; the vitamins likely provided nutritional support to the follicle environment rather than direct anti-hair-loss activity.
Original Study Citation
Moftah, N., Abd-Elaziz, G., Ahmed, N., Hamed, Y., Ghannam, B., & Ibrahim, M. (2013). Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. Journal of the European Academy of Dermatology and Venereology, 27(6), 686–693. https://doi.org/10.1111/j.1468-3083.2012.04535.x
How to Cite This Summary
APA: Hairgenetix. (2025). Mesotherapy for female hair loss: 62.8% showed improvement — Plain-language study summary. Hairgenetix Research Library. https://hairgenetix.com/blogs/articles/mesotherapy-female-hair-loss-dutasteride-moftah-2013
Informal: According to a 2013 clinical trial of 126 women published in JEADV, dutasteride mesotherapy produced photographic improvement in 62.8% of patients compared to 17.5% with placebo (Moftah et al., 2013). Summarised by Hairgenetix at hairgenetix.com.
Related Research on Hairgenetix
Why Hairgenetix Focuses on Science-Backed Treatments
This study demonstrates that delivering active ingredients directly to the scalp — rather than relying on surface application alone — produces significantly better results. This delivery principle is at the core of the Hairgenetix approach.
Our copper peptide serum is formulated to work with at-home microneedling, creating micro-channels that enhance ingredient penetration — the same concept that makes clinical mesotherapy so effective, adapted for safe home use. Combined with our derma roller system, you can apply the science of enhanced scalp delivery without clinical visits.
Browse the Hairgenetix Collection →